On September 24, REMEGEN fell 5.08% in regular trading, trading at 75.5 HKD/share, with turnover of approximately 35.35 million HKD. The decline came as the broader biotechnology sector weakened and the market continued to digest concerns over the sustainability of the company's profit structure.

REMEGEN reported H1 revenue of 5.853 billion yuan, up 433% year-over-year, and net profit of 4.662 billion yuan, swinging from a loss of 450 million yuan a year earlier. However, the bulk of the profit was driven by a one-time 6.5 billion USD upfront payment from an exclusive licensing deal with AbbVie for RC148, with management noting an underlying net loss of approximately 26 million yuan excluding BD income. An executive director also reduced holdings of roughly 20,000 H shares in late August, weighing on sentiment. Analysts project revenue and profit to decline significantly next year, reflecting caution over high-growth sustainability.

Within the Biotechnology sector, stocks broadly declined. Among peers, AKESO fell 2.72%, 3SBIO fell 2.06%, INNOVENT BIO fell 1.74%, BEONE MEDICINES fell 0.27%, and INNOGEN-B fell 0.24%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)